ReviewWorld journal of cardiology2023
Proton pump inhibitors and gastroprotection in patients treated with antithrombotic drugs: A cardiologic point of view.
Review in World journal of cardiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 26 citations in OpenAlex.
- Incidence and Predictors of Anticoagulant-Associated Bleeding in Patients With Venous Thromboembolism.Journal of clinical medicine research · 2026Article
- Proton pump inhibitors are associated with increased risk of pseudoarthrosis after lumbar fusion.North American Spine Society journal · 2026Article
- Trends and inequities in peptic ulcer mortality across the United States, 1999-2023.BMC gastroenterology · 2026Article
- Low-Dose Aspirin Induced Gastric Ulcer in a Patient With TIA: A Clinical Caution for Aspirin Therapy Without Gastroprotection.Clinical case reports · 2026Article
- Prescribing Practices, Polypharmacy, and Drug Interaction Risks in Anticoagulant Therapy: Insights from a Secondary Care Hospital.Journal of clinical medicine · 2026Article
- Thrombotic complications of glucocorticoids and anabolic steroids.Research and practice in thrombosis and haemostasis · 2025Review
- Analysis of Upper Gastrointestinal Adverse Events Associated with Oral Anticoagulants and Potential Drug Interactions with Cardiovascular Drugs: Exploratory Study Using FDA Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Proton Pump Inhibitors (PPIs)-An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing.Medicina (Kaunas, Lithuania) · 2025Review
- Trends in Proton Pump Inhibitor Use in Sweden by Sex and Age: A Drug Utilisation Study.Drug safety · 2025Article
- Risk of Lower Gastrointestinal Bleeding in Nonsteroidal Anti-inflammatory Drug (NSAID) and Proton Pump Inhibitor Users Compared with NSAID-Only Users: A Common Data Model Analysis.Gut and liver · 2025Observational
- Risk Factors for Upper Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy with Assessment of Anti-Ulcer Medication Effects.Acta Cardiologica Sinica · 2025Article
- Systemic Toxicity Profile of Chemotherapeutic Agents in a Wistar Rat Model: A Preliminary Report.Journal of toxicology · 2025Article
- Cardiotoxic effects of pantoprazole in Wistar rats submitted to cardiac ischemia and reperfusion.Revista da Associacao Medica Brasileira (1992) · 2025Article
- Rosuvastatin-based combination treatment with acetylsalicylic acid or ezetimibe in the management of patients at high and very high cardiovascular risk. Expert opinion paper of the Polish Lipid Association 2025.Archives of medical science : AMS · 2025Article
- Risk factors and predictive model for gastrointestinal bleeding in patients with ischemic stroke: a case-control study.American journal of translational research · 2025Article
- Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors.Frontiers in pharmacology · 2025Review
- Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study.Drugs & aging · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aspirin, other antiplatelet agents, and anticoagulant drugs are used across a wide spectrum of cardiovascular and cerebrovascular diseases. A concomitant proton pump inhibitor (PPI) treatment is often prescribed in these patients, as gastrointestinal complications are relatively frequent. On the other hand, a potential increased risk of cardiovascular events has been suggested in patients treated with PPIs; in particular, it has been discussed whether these drugs may reduce the cardiovascular protection of clopidogrel, due to pharmacodynamic and pharmacokinetic interactions through hepatic metabolism. Previously, the concomitant use of clopidogrel and omeprazole or esomeprazole has been discouraged. In contrast, it remains less known whether PPI use may affect the clinical efficacy of ticagrelor and prasugrel, new P2Y12 receptor antagonists. Current guidelines recommend PPI use in combination with antiplatelet treatment in patients with risk factors for gastrointestinal bleeding, including advanced age, concurrent use of anticoagulants, steroids, or non-steroidal anti-inflammatory drugs, and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.